<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Division of Breast Cancer Research</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B8E600E-360E-4129-ADD9-D3D2BAD11EA7"><gtr:id>7B8E600E-360E-4129-ADD9-D3D2BAD11EA7</gtr:id><gtr:firstName>Philippa</gtr:firstName><gtr:otherNames>Madeleine</gtr:otherNames><gtr:surname>Hewish</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0802325"><gtr:id>E847D817-8B9B-4A72-8E95-A1129F4383B8</gtr:id><gtr:title>Identification and development of synthetic lethal strategies and predictive biomarkers for therapy for MMR Deficient Co</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0802325</gtr:grantReference><gtr:abstractText>We aim to identify and develop new ways of treating a particular type of large bowel cancer, caused by a defect in how DNA is repaired. At present, about 17% of cases of large bowel cancer have evidence of a deficiency in a DNA repair pathway called Mismatch Repair (MMR). This affects both young patients, who mainly have an inherited form of MMR deficiency, Lynch Syndrome, and older patients, who spontaneously develop a defect in one of the MMR genes. 

Using advanced molecular biology techniques to screen for potential drug targets, we aim to identify and develop those that could be of use in the clinical treatment of MMR deficient large bowel cancer, with the intention of taking them forwards into drug trials. The laboratory research will be based at the Institute of Cancer Research, and the clinical research at The Royal Marsden Hospital. In tandem with the development of new therapeutic strategies, we will also develop biomarkers. These are substances that can be tested in patient samples to predict whether they are likely to respond to a specific treatment or not.</gtr:abstractText><gtr:technicalSummary>Current practice in oncology mainly treats tumours by grouping together similar phenotypes, rather than determining therapy by analysis of the underlying molecular genotype. This results in reduced response rates and excess toxicity.
Accurate repair of DNA is essential to the stability of the genome and consequently defective DNA repair is associated with tumourigenesis. 17% of colorectal carcinoma (CRC) is characterised by defects in the DNA mismatch repair (MMR) pathway. Germline mutations in the major MMR genes (MLH1, MSH2, PMS2, MSH6), causing Lynch syndrome, account for up to 5%, whilst the remaining 12% are caused by somatic epigenetic changes, mainly involving the MLH1 promoter.
This project aims to explore underlying defects in the MMR pathway as therapeutic targets in CRC, by utilising the concept of synthetic lethality (SL) to identify tumour-selectivity. Two genes are SL if a mutation in either gene alone is compatible with cellular viability, but the loss of both genes together results in cell death. Identified targets will be analysed for potential application in the clinical setting, concurrently developing predictive biomarkers. 
Project aims:
1) Performance of siRNA kinome screen to identify kinases whose loss of expression is synthetically lethal with deficiency of MLH1. An MLH1 deficient in vitro cell line model will be used with an isogenic MLH1 proficient comparator. Identified ?hits? will be taken forwards for further mechanistic investigation, with the aim of identifying new therapeutic targets for clinical practice.
2) Performance of small molecule inhibitor screens to identify compounds where treatment causes selective cell death in the presence of MLH1 deficiency when compared to isogenic MLH1 proficient comparators. Identified compounds will be investigated for mechanism and clinical significance. 
3) Analysis of samples from a therapeutic drug trial based on recent observations from this laboratory, treating CRC patients with MSHficiency with methotrexate, in tandem with the analysis of samples from methotrexate-treated patients with presumed MMR competency. In vitro studies have suggested that selective cell death occurs in MSH2 deficient cells on treatment with methotrexate, and that cell death is associated with an increase in the oxidative damage lesion, 8-OHdG. Human biological samples (leucocytes, serum and urine) will be analysed to evaluate the oxidative lesion, 8-OHdG, as a biomarker of treatment response. 
Outline plan:
Year 1: Performance of primary and secondary siRNA kinome screens
Year 2: Tertiary screen, mechanistic studies, performance of small molecule inhibitor
screen and validation, analysis of tissue samples
Year 3: Mechanistic studies, analysis of tissue samples and biomarker development, thesis writing</gtr:technicalSummary><gtr:fund><gtr:end>2012-05-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-05-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>231160</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>MMR and Synthetic lethality</gtr:description><gtr:id>E3205982-2156-43E2-8DF2-841ED7C17A97</gtr:id><gtr:impact>Publication under review</gtr:impact><gtr:outcomeId>JbQgYFt5Wdo-1</gtr:outcomeId><gtr:partnerContribution>Supply of materials and reagents</gtr:partnerContribution><gtr:piContribution>Identification a gene that is synthetically lethal with MMR deficiency</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Fund raisers for Royal Marsden Hospital</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>44890DC7-3A50-4DE6-A012-7B8730852841</gtr:id><gtr:impact>Article distributed to large audience

none known</gtr:impact><gtr:outcomeId>bp3khaUz6hb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Colorectal cancer focus on translational research</gtr:description><gtr:form>Scientific meeting (conference/symposium etc.)</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A3D61BDD-89AA-4F7B-81B1-F94B93E65CED</gtr:id><gtr:impact>Approximately 70 attendees from the department and collaborators and potential collaborators

Increased collaboration across the RMH and ICR between physicians and scientists</gtr:impact><gtr:outcomeId>Me8fGzBcf3s</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Colorectal Cancer study day at Royal Marsden Hospital</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E3C70DD7-1D34-4897-9FD5-F4F03A6BADBA</gtr:id><gtr:impact>Talk on translational science in colorectal cancer to visiting Professors (surgeons and physicians) from China

Good feedback received</gtr:impact><gtr:outcomeId>aFxSt3EeBAk</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talks for ICR fundraisers</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>94DD8967-049E-4447-8E5B-DDA69486F56A</gtr:id><gtr:impact>Talks to individuals and small groups involved in philanthropic activites for the Institute of Cancer Research, including members of Parliament and policymakers

Increased philanthropic activity for the Institute of Cancer Research. Positive feedback from attendees.</gtr:impact><gtr:outcomeId>joZWKEiUcd3</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Open days for Breakthrough Breast Cancer</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>776CB584-5B01-44D0-B6E3-685B6EAB61EE</gtr:id><gtr:impact>Talks lab tours for groups of fundraisers at the Institute of Cancer Research (approximately 200 people attended on each occasion)

Increased funding for Breakthrough Breast Cancer</gtr:impact><gtr:outcomeId>EdS5NKkVicM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010,2011,2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B60F67FE-951E-4616-98AA-5EDA007B5F14</gtr:id><gtr:title>First-line treatment of advanced colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cdfd55c2a3d3a3f9827e730f03625b7"><gtr:id>9cdfd55c2a3d3a3f9827e730f03625b7</gtr:id><gtr:otherNames>Hewish M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>pm_16345_25_21641637</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22BDB9CD-F9F4-4457-9F8B-A538B60543C5</gtr:id><gtr:title>Genomic instability and the selection of treatments for cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae416a1098ac7ec4c163f5e4a1a104f9"><gtr:id>ae416a1098ac7ec4c163f5e4a1a104f9</gtr:id><gtr:otherNames>Martin SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>MyiedPhs5Tj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C411BDA8-3BD2-4C76-B46D-19D69B82CB0E</gtr:id><gtr:title>Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae416a1098ac7ec4c163f5e4a1a104f9"><gtr:id>ae416a1098ac7ec4c163f5e4a1a104f9</gtr:id><gtr:otherNames>Martin SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>AiKPaVwYj3Q</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B4A8B9-AA7D-495A-BC13-F6B7F9061DD0</gtr:id><gtr:title>Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cdfd55c2a3d3a3f9827e730f03625b7"><gtr:id>9cdfd55c2a3d3a3f9827e730f03625b7</gtr:id><gtr:otherNames>Hewish M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_16345_25_23361057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A06BAB85-F338-430C-9DB3-673A566CFAF3</gtr:id><gtr:title>Mismatch repair deficient colorectal cancer in the era of personalized treatment.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Clinical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9cdfd55c2a3d3a3f9827e730f03625b7"><gtr:id>9cdfd55c2a3d3a3f9827e730f03625b7</gtr:id><gtr:otherNames>Hewish M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1759-4774</gtr:issn><gtr:outcomeId>enEEevoxata</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0802325</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>67</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>